The emergence of drugs like copyright and Semaglutide signifies a major shift in how we treat metabolic disorders. These innovative therapies belong to a class known as GLP-1 action agonists, which mimic the effects of a natural hormone that manages glucose levels and food intake. Originally, developed for managing blood sugar, their effectiveness